









Markets
/
Stocks
/
nasdaq-gild
/

Gilead Sciences Inc

GILD



View Detailed Chart

120.400USD

-2.810-2.28%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

149.54BMarket Cap

18.49P/E TTM



Gilead Sciences Inc

120.400

-2.810-2.28%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-2.28%

5 Days

-0.68%

1 Month

-3.70%

6 Months

+9.47%

Year to Date

+30.35%

1 Year

+31.08%

View Detailed Chart

TradingKey Stock Score of Gilead Sciences Inc

Currency: USD Updated: 2025-12-12

Key Insights

Gilead Sciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 15/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 131.15.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gilead Sciences Inc's Score

Industry at a Glance

Industry Ranking

15 / 159

Overall Ranking

62 / 4592

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 31 analysts

Buy

Current Rating

131.154

Target Price

+8.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gilead Sciences Inc Highlights

StrengthsRisks

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 814.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 814.79%.

Fairly Valued

The company’s latest PE is 18.49, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.13B shares, increasing 0.00% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 1.37K shares of this stock.

Gilead Sciences Inc News

Why Gilead Sciences Stock Just Popped

Biopharmaceuticals stock Gilead Sciences (NASDAQ: GILD) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded the shares to a buy rating and slapped a $133 price target on the $116 stock.

The Motley FoolFri, Jul 25

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13